ASIAN BIOMEDICINE, vol.4, no.4, pp.627-630, 2010 (SCI-Expanded)
Background: Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (U FT).